A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging

[1]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[2]  Myeong-Jin Kim.  Improving Survival with Gadoxetic Acid-enhanced MRI for Hepatocellular Carcinoma. , 2020, Radiology.

[3]  Young Kon Kim,et al.  Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis. , 2020, Radiology.

[4]  Shriti Singh,et al.  Challenges in liver cancer and possible treatment approaches. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[5]  Ivo F Scheiber,et al.  The intestinal metal transporter ZIP14 maintains systemic manganese homeostasis , 2019, The Journal of Biological Chemistry.

[6]  S. Wilhelm,et al.  Elimination Pathways of Nanoparticles. , 2019, ACS nano.

[7]  Xiaoli Liu,et al.  Composition-Tunable Ultrasmall Manganese Ferrite Nanoparticles: Insights into their In Vivo T1 Contrast Efficacy , 2019, Theranostics.

[8]  P. Nellist,et al.  Targeted T1 Magnetic Resonance Imaging Contrast Enhancement with Extraordinarily Small CoFe2O4 Nanoparticles , 2019, ACS applied materials & interfaces.

[9]  Yongmin Chang,et al.  Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent. , 2018, Bioconjugate chemistry.

[10]  G. Mauri,et al.  Management of Biliary Strictures: State-of-the-Art Review. , 2018, Radiology.

[11]  P. Caravan,et al.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. , 2018, Chemical reviews.

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  Eric M Gale,et al.  Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation. , 2018, Journal of medicinal chemistry.

[14]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[15]  R. Weiskirchen,et al.  SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice , 2018, Proceedings of the National Academy of Sciences.

[16]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[17]  Hsiao-Ying Wey,et al.  A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. , 2017, Radiology.

[18]  Richard A. Revia,et al.  Nanoparticle Biokinetics in Mice and Nonhuman Primates. , 2017, ACS nano.

[19]  Philip S Low,et al.  Ligand-Targeted Drug Delivery. , 2017, Chemical reviews.

[20]  T. Hyeon,et al.  Iron oxide nanoclusters for T1 magnetic resonance imaging of non-human primates , 2017, Nature Biomedical Engineering.

[21]  Yingying Yu,et al.  Manganese transporter Slc39a14 deficiency revealed its key role in maintaining manganese homeostasis in mice , 2017, Cell Discovery.

[22]  Seung-Min Park,et al.  Towards clinically translatable in vivo nanodiagnostics. , 2017, Nature reviews. Materials.

[23]  B. Bay,et al.  Ultrasmall Ferrite Nanoparticles Synthesized via Dynamic Simultaneous Thermal Decomposition for High-Performance and Multifunctional T1 Magnetic Resonance Imaging Contrast Agent. , 2017, ACS nano.

[24]  Yongmin Chang,et al.  Manganese Complex of Ethylenediaminetetraacetic Acid (EDTA)-Benzothiazole Aniline (BTA) Conjugate as a Potential Liver-Targeting MRI Contrast Agent. , 2017, Journal of medicinal chemistry.

[25]  Harald Ittrich,et al.  Exceedingly small iron oxide nanoparticles as positive MRI contrast agents , 2017, Proceedings of the National Academy of Sciences.

[26]  J. Langhoff‐Roos.  State‐of‐the‐art review , 2016, Acta obstetricia et gynecologica Scandinavica.

[27]  Ian D. McGilvray,et al.  Mechanism of hard nanomaterial clearance by the liver , 2016, Nature materials.

[28]  I. Aoki,et al.  A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. , 2016, Nature nanotechnology.

[29]  Stephen W. Wilson,et al.  Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia , 2016, Nature Communications.

[30]  T. Murakami,et al.  Biochemical and Clinical Predictive Approach and Time Point Analysis of Hepatobiliary Phase Liver Enhancement on Gd-EOB-DTPA-enhanced MR Images: A Multicenter Study. , 2016, Radiology.

[31]  K. Boberg,et al.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.

[32]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[33]  B. V. Van Beers,et al.  Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. , 2016, Journal of hepatology.

[34]  L. Decosterd,et al.  Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. , 2016, Radiology.

[35]  Yixiang Wang.  Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging. , 2015, World journal of gastroenterology.

[36]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[37]  Wei Zheng,et al.  Manganese Toxicity Upon Overexposure: a Decade in Review , 2015, Current Environmental Health Reports.

[38]  C. Sirlin,et al.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. , 2014, Radiology.

[39]  Jin-Young Choi,et al.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. , 2014, Radiology.

[40]  F. Fang,et al.  Anchoring Group Effects of Surface Ligands on Magnetic Properties of Fe3O4 Nanoparticles: Towards High Performance MRI Contrast Agents , 2014, Advanced materials.

[41]  J. Ding,et al.  Coating Engineering of MnFe2O4 Nanoparticles with Superhigh T2 Relaxivity and Efficient Cellular Uptake for Highly Sensitive Magnetic Resonance Imaging , 2014 .

[42]  B. Choi,et al.  Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. , 2014, Radiology.

[43]  M. Aschner,et al.  Manganese neurotoxicity and the role of reactive oxygen species. , 2013, Free radical biology & medicine.

[44]  E. Merkle,et al.  MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography? , 2013, AJR. American journal of roentgenology.

[45]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[46]  H. Hussain,et al.  Primovist, Eovist: what to expect? , 2012, Journal of hepatology.

[47]  Rui Hu,et al.  A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. , 2012, Nature nanotechnology.

[48]  Cem Balcı,et al.  Diagnostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the Evaluation of the Biliary Obstruction , 2012, TheScientificWorldJournal.

[49]  Y. Ni,et al.  Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-day dynamic results. , 2012, European journal of radiology.

[50]  Taeghwan Hyeon,et al.  Large-scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. , 2011, Journal of the American Chemical Society.

[51]  Ji-Eun Kim,et al.  Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. , 2011, AJR. American journal of roentgenology.

[52]  Taeghwan Hyeon,et al.  Mesoporous Silica-Coated Hollow Manganese Oxide Nanoparticles as Positive T1 Contrast Agents for Labeling and MRI Tracking of Adipose-Derived Mesenchymal Stem Cells , 2011, Journal of the American Chemical Society.

[53]  Yi-Xiang J. Wang.  Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. , 2011, Quantitative imaging in medicine and surgery.

[54]  M. Wallace,et al.  Quality improvement guidelines for percutaneous transhepatic cholangiography, biliary drainage, and percutaneous cholecystostomy. , 2010, Journal of vascular and interventional radiology : JVIR.

[55]  Elias Provencio-Vasquez,et al.  A decade in review , 2010 .

[56]  Yongmin Chang,et al.  Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. , 2007, Biomaterials.

[57]  R. Harrington.  Part II , 2004, Bitter Freedom.

[58]  W. Schima,et al.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications , 2004, European Radiology.

[59]  T. Skotland,et al.  Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR , 2002, JBIC Journal of Biological Inorganic Chemistry.

[60]  D. Schilling,et al.  Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study , 2000, The Lancet.

[61]  T. Skotland,et al.  Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood. , 1997, Journal of pharmaceutical and biomedical analysis.

[62]  Louise Poissant.  Part I , 1996, Leonardo.

[63]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[64]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[65]  B. Choi,et al.  Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. , 2015, Radiology.

[66]  R. Faletti,et al.  Multiparametric Gd-EOB-DTPA magnetic resonance in diagnosis of HCC: dynamic study, hepatobiliary phase, and diffusion-weighted imaging compared to histology after orthotopic liver transplantation , 2014, Abdominal Imaging.

[67]  Y. Ni,et al.  In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes. , 2014, Biomaterials.

[68]  M. Freeman,et al.  ERCP cannulation: a review of reported techniques. , 2005, Gastrointestinal endoscopy.

[69]  R. Semelka,et al.  Contrast agents for MR imaging of the liver. , 2001, Radiology.

[70]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.